Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemiain adult patients with cold agglutinin disease
- Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease
Paris, November17, 2022. The European Commission (EC) has granted marketing authorization for Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chronic autoimmune hemolytic anemia, where the body’s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as hemolysis.
Dietmar Berger, MD, PhD
Chief Medical Officer, Global Head of Development at Sanofi
“This approval highlights our ambition to develop first- and best-in-class medicines that transform people’s lives. Up until now, patients in Europe had to rely on a combination of cold avoidance, blood transfusions and off-label treatments to manage their disease. The approval of Enjaymo by the European Commission provides patients, for the first time, with access to a therapy that can make a meaningful difference in the treatment and daily experience of living with CAD.”
Enjaymo is currently the only approved treatment for CAD and is a first-in-class humanized monoclonal antibody that is designed to selectively target and inhibit the classical complement pathway specific serine protease, C1s. It will be available as a 50mg/mL solution for infusion.
Alexander Röth, MD
Department of Hematology and Stem Cell Transplantation, University Hospital, University of Duisburg-Essen, Germany
“Coupled with diagnostic journeys that can last years, the impact of fatigue on quality of life in CAD is often debilitating and is comparable to conditions such as cancer-related anemia and other autoimmune disorders.Clinicians now have a much-needed therapeutic option to offer to their patients.”
About the CADENZA and CARDINAL Clinical Trials
The EC approval is based on data from two Phase 3 clinical trials: CADENZA, a double-blind, placebo-controlled clinical trial of adults with CAD without a recent history of blood transfusion (within the past 6 months), and CARDINAL, a 26-week open label, single-arm pivotal study in patients with CAD who have had a recent blood transfusion.
In the CADENZA Part A trial, eligible patients were randomized 1:1 to receive a fixed weight-based dose (6.5g or 7.5g) of Enjaymo or placebo via intravenous infusion on Day 0, Day 7, and then once every other week up to Week 26. The open-label Part B of the study assessed long-term safety as well as durability of response to Enjaymo in patients with CAD. In the CADENZA Part A study, Enjaymo met its primary composite endpoint and all secondary endpoints and demonstrated inhibition of hemolysis, increase in hemoglobin levels, and clinically meaningful improvement in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores. Enjaymo demonstrated an acceptable safety profile and was generally well-tolerated. 96% of patients in the Enjaymo group and 100% of patients in the placebo group experienced at least one treatment emergent adverse event (TEAE). Headache (22.7% vs 10.0%), hypertension (22.7% vs 0%), rhinitis (18.2% vs 0%), Raynaud phenomenon (18.2% vs 0%), and acrocyanosis (13.6% vs 0%) were reported more frequently in Enajymo-treated patients compared with placebo.
In the CARDINAL Part A trial, patients received a fixed weight-based dose (6.5g or 7.5g) of Enjaymo via intravenous infusion on Day 0, Day 7, and then once every other week up to Week 26. Part B of the study evaluated the long-term safety as well as durability of response to Enjaymo in patients with CAD over a 2-year follow up. In the CARDINAL Part A study, the efficacy of Enjaymo was assessed based on the achievement of a primary composite endpoint (Hb≥12 g/dL or an increase of at least 2 g/dL; no blood transfusion or prohibited medications from Weeks 5 through 26) and different secondary endpoints, including improvements in hemoglobin, normalization of bilirubin, and FACIT-fatigue score. The most common adverse reactions occurring in 10% or more of patients were respiratory tract infection, viral infection, diarrhea, dyspepsia, cough, arthralgia, arthritis, and peripheral edema. Serious adverse reactions were reported in 13% (3/24) of patients who received Enjaymo. These serious adverse reactions were streptococcal sepsis and staphylococcal wound infection (n=1), arthralgia (n=1), and respiratory tract infection (n=1).
About Enjaymo® (sutimlimab)
Enjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, Enjaymo inhibits the activation of the complement cascade in the immune system and inhibits C1-activated hemolysis in CAD to prevent the abnormal destruction of healthy red blood cells. Enjaymo does not inhibit the lectin and alternative pathways. Enjaymo was approved by the US Food and Drug Administration (FDA) in February 2022 as the first and only treatment indicated to decrease the need for red blood cell transfusion due to hemolysis in adults with CAD. The Japanese Ministry of Health, Labor and Welfare approved Enjaymo in June 2022. The European Medicines Agency (EMA) also made the decision to maintain orphan designation.
About cold agglutinin disease
Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia, where part of the body’s immune system mistakenly destroys healthy red blood cells (hemolysis). CAD impacts the lives of an estimated 12,000 people in the US, Europe, and Japan and is associated with profound fatigue and increased risk of thromboembolic events and mortality.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | email@example.com
Arnaud Delépine| + 33 6 73 69 36 93 | firstname.lastname@example.org
Corentine Driancourt | + 33 6 40 56 92 21 | email@example.com
Felix Lauscher | + 1 908 612 7239 | firstname.lastname@example.org
Priya Nanduri | + 1 617 764 6418| email@example.com
Nathalie Pham | + 33 7 85 93 30 17 | firstname.lastname@example.org
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions1.2.2023 15:40:00 CET | Press release
Talenom Plc, Stock Exchange Release 1 February 2023 at 16:40 EET The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions Talenom Plc announced two acquisitions on 1 February 2023. Part of the purchase prices will be paid in cash and part with new shares of Talenom Plc subscribed in a directed share issue. The transaction prices are not disclosed. As part of the transactions, Talenom has decided to issue 50,825 new shares in a directed share issue for the sellers of the acquisition targets, i.e., BKF Asesores, S.L. and R2 Redovisning Ab. The subscription date for the shares is 1 February 2023. The number of new shares to be issued corresponds with some 0.11 percent of all Talenom Plc's shares prior to the share issue. After the registration of the new shares the total number of shares in Talenom Plc is 44,986,213 shares. The new shares will carry shareholder rights as of their registration day, estimated on 3 February 2023. The shares issued i
Talenom expands its operations in Spain by acquiring an accounting firm in Madrid1.2.2023 15:35:00 CET | Press release
Talenom Plc, press release 1 February 2023 at 16:35 EET Talenom expands its operations in Spain by acquiring an accounting firm in Madrid Talenom Plc has agreed to acquire the entire share capital of BKF Asesores, S.L., an accounting firm operating in Madrid, Spain. The acquired business will be transferred to Talenom on 1 February 2023. BKF Asesores, S.L. provides accounting, payroll and advisory services mainly to SMEs. The net sales transferred to Talenom from the acquired business is some EUR 0.7 million annually. The company employs a total of nine persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 85
Talenom acquires the Swedish accounting firm R2 Redovisning Ab1.2.2023 15:30:00 CET | Press release
Talenom Plc, press release 1 February 2023 16:30 EET Talenom acquires the Swedish accounting firm R2 Redovisning Ab Talenom Plc has agreed to acquire the entire share capital of R2 Redovisning Ab. The acquired business will be transferred to Talenom on 1 February 2023. R2 Redovisning Ab operates in Gothenburgh and Kungsbacka. The company provides accounting, payroll and advisory services mainly to SMEs. The yearly net sales transferred to Talenom from the acquired business is approximately EUR 0.7 million. The company employs a total of seven persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 8554 otto-pek
Ordinær generalforsamling Ringkjøbing Landbobank A/S1.2.2023 15:28:56 CET | pressemeddelelse
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Øvrige interessenter Dato 01.02.2023 Ordinær generalforsamling i Ringkjøbing Landbobank A/S Der afholdes ordinær generalforsamling onsdag, den 1. marts 2023, kl. 17.00 i ROFI-Centret, Kirkevej 26, Rindum, 6950 Ringkøbing. Dagsorden i henhold til vedtægterne 1. Valg af dirigent Bestyrelsen foreslår advokat Allan Østergaard Sørensen som dirigent. 2.Bestyrelsens beretning om bankens virksomhed i det forløbne år Bestyrelsen foreslår, at bestyrelsens beretning tages til efterretning. 3.Fremlæggelse af årsrapporten til godkendelse Bestyrelsen foreslår, at årsrapporten godkendes. Der henvises endvidere til den offentliggjorte årsrapport for 2022. 4.Beslutning om anvendelse af overskud eller dækning af tab i henhold til den godkendte årsrapport Bestyrelsen foreslår, at resultatdisponeringen godkendes. Der henvises endvidere til den offentliggjorte årsrapport for 2022. 5.Vejledende afstemning om vederlagsrapport Bestyrelsen foreslår, at ve
Annual general meeting of Ringkjøbing Landbobank A/S1.2.2023 15:28:56 CET | Press release
Nasdaq Copenhagen London Stock Exchange Euronext Dublin Other stakeholders Date 01.02.2023 Annual general meeting of Ringkjøbing Landbobank A/S The bank will hold its annual general meeting at 5:00 p.m. on Wednesday, 1 March 2023 at the ROFI Centre, Kirkevej 26, Rindum, 6950 Ringkøbing. Agenda as per the articles of association: 1. Election of chairperson The board of directors proposes that Allan Østergaard Sørensen, attorney-at-law, chair the meeting. 2.The board's report on the bank’s activities in the previous year The board of directors proposes that the board’s report be adopted. 3.Presentation of the annual report for approval The board of directors proposes that the annual report be approved. Further reference is made to the published annual report for 2022. 4.Decision on allocation of profit or covering of loss under the approved annual report The board of directors proposes that the distribution of profit be approved. Further reference is made to the published annual report f